Company
Headquarters: Tokushima, Japan
Employees: 11
¥6.72 Billion
JPY as of Jan. 1, 2026
US$42.9 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323 to treat lung cancer; DFP-17729, DFP-11207, and DFP-14927 for the treatment of solid tumors; and DFP-10825 for peritoneal metastasis. The company was founded in 2010 and is headquartered in Tokushima, Japan.
Delta-Fly Pharma, Inc. has the following listings and related stock indices.
Stock: JPX: 4598